Figure 3. PLX3397 treatment decreased the number of microglia and BrdU-positive proliferative cells. A: PLX3397, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, is treated to neonatal mice by intraperitoneal injection
(twice daily) to deplete the microglia. B, C: The treatment decreases the number of Iba-1-positive microglia (red). D, E: PLX3397 decreases the number of 5-bromo-2′-deoxyuridine (BrdU)-positive proliferative cells (red). F, G: PLX3397 decreases the BrdU and retinal precursor cell markers, Chx10 or Pax6 (green) double-positive cells. The quantitative
data show the decrease in the BrdU and Chx10 double-positive cells by PLX3397 treatment. H: PLX3397 does not alter the cleaved caspase-3-positive cells. Data are the mean ± standard error of the mean (SEM; n=4).
#p<0.05 versus control (Dunnett’s test). Scale bar=20 μm.